July 23rd 2024
A combined genomic and histological analysis within trial datasets demonstrates a sound tumor evaluation strategy for patients with prostate cancer.
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Pembrolizumab Plus Olaparib Did Not Improve PFS and OS in mCRPC
September 12th 2022Result from the phase 3 KEYLINK-010 trial showed no statistically significant improvement in radiographic progression-free survival and overall survival when pembrolizumab and olaparib were used to treat molecularly unselected, previously treated metastatic castration-resistant prostate cancer vs novel hormonal agents.
Enzalutamide Plus Abiraterone Acetate and Prednisolone Not Recommended for mHSPC
September 11th 2022Despite the combination of enzalutamide plus abiraterone acetate and prednisolone (AAP) falling short in patients with metastatic hormone-sensitive prostate cancer, although androgen deprivation therapy plus AAP resulted in a clinically meaningful overall survival benefit.
FDA Gives Priority Review to Olaparib and Abiraterone for mCRPC Regardless of HRR Status
August 16th 2022Based on data showing that patients with metastatic castration-resistant prostate cancer may achieve benefit following treatment with olaparib plus abiraterone and prednisone or prednisolone regardless of homologous recombination repair mutational status, the FDA gave the combination priority review.